Literature DB >> 15196705

Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.

Esther Weiss-Messer1, Osnat Merom, Ayala Adi, Rachel Karry, Maslama Bidosee, Rosalie Ber, Alexander Kaploun, Avi Stein, Ronnie J Barkey.   

Abstract

Various hormones and growth factors have been implicated in progression of prostate cancer, but their role and the underlying molecular mechanism(s) involved remain poorly understood. In this study, we investigated the role of human growth hormone (GH) and its receptor (GHR) in human prostate cancer. We first demonstrated mRNA expression of GHR and of its exon 9-truncated isoform (GHR(tr)) in benign prostate hyperplasia (BPH) and prostate adenocarcinoma patient tissues, as well as in LNCaP, PC3 and DU145 human prostate cancer cell lines. GHR mRNA levels were 80% higher and GHR(tr) only 25% higher, in the carcinoma tissues than in BPH. Both isoforms were also expressed in LNCaP and PC3 cell lines and somewhat less so in DU145 cells. The LNCaP cell GHR protein was further characterized, on the basis of its M(r) of 120kDa, its binding to two different GHR monoclonal antibodies, its high affinity and purely somatogenic binding to (125)I-hGH and its ability to secrete GH binding protein, all characteristic of a functional GHR. Furthermore, GH induced rapid, time- and dose-dependent signaling events in LNCaP cells, including phosphorylation of JAK2 tyrosine kinase, of GHR itself and of STAT5A (JAK2-STAT5A pathway), of p42/p44 MAPK and of Akt/PKB. No effect of GH (72h) could be shown on basal or androgen-induced LNCaP cell proliferation nor on PSA secretion. Interestingly, however, GH caused a rapid (2-12h) though transient striking increase in immunoreactive androgen receptor (AR) levels (< or =5-fold), followed by a slower (24-48h) reduction (< or = 80%), with only modest parallel changes in serine-phosphorylated AR. In conclusion, the GH-induced activation of signaling pathways, its effects on AR protein in LNCaP cells and the isoform-specific regulation of GHR in prostate cancer patient tissues, suggest that GH, most likely in concert with other hormones and growth factors, may play an important role in progression of human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196705     DOI: 10.1016/j.mce.2004.03.004

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  24 in total

Review 1.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Authors:  M Victoria Recouvreux; J Boyang Wu; Allen C Gao; Svetlana Zonis; Vera Chesnokova; Neil Bhowmick; Leland W Chung; Shlomo Melmed
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

Review 3.  Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.

Authors:  Eric M Jacobson; Eric R Hugo; Traci R Tuttle; Ruben Papoian; Nira Ben-Jonathan
Journal:  Trends Endocrinol Metab       Date:  2010-09-16       Impact factor: 12.015

4.  Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression.

Authors:  Makoto Anzo; Laura J Cobb; David L Hwang; Hemal Mehta; Jonathan W Said; Shoshana Yakar; Derek LeRoith; Pinchas Cohen
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

5.  The prostate of weaned pups is altered by maternal malnutrition during lactation in rats.

Authors:  Cristiane da F Ramos; Marcio A Babinski; Waldemar S Costa; Francisco J B Sampaio
Journal:  Asian J Androl       Date:  2009-11-10       Impact factor: 3.285

6.  Growth hormone promotes lymphangiogenesis.

Authors:  Nadja Erika Banziger-Tobler; Cornelia Halin; Kentaro Kajiya; Michael Detmar
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

7.  Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen.

Authors:  Eric P Rahrmann; Lara S Collier; Todd P Knutson; Meghan E Doyal; Sheri L Kuslak; Laura E Green; Rita L Malinowski; Laura Roethe; Keiko Akagi; Michelle Waknitz; Wei Huang; David A Largaespada; Paul C Marker
Journal:  Cancer Res       Date:  2009-04-28       Impact factor: 12.701

8.  Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

Authors:  Pooja G Talati; Lei Gu; Elyse M Ellsworth; Melanie A Girondo; Marco Trerotola; David T Hoang; Benjamin Leiby; Ayush Dagvadorj; Peter A McCue; Costas D Lallas; Edouard J Trabulsi; Leonard Gomella; Andrew E Aplin; Lucia Languino; Alessandro Fatatis; Hallgeir Rui; Marja T Nevalainen
Journal:  Am J Pathol       Date:  2015-09       Impact factor: 4.307

Review 9.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers.

Authors:  Shyh-Han Tan; Marja T Nevalainen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 10.  Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.

Authors:  Zhiyong Liao; Jacqueline Lutz; Marja T Nevalainen
Journal:  Int J Biochem Cell Biol       Date:  2009-11-13       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.